PMC9811588_01
The patient's Patient Health Questionnaire (PHQ-9) scores 8 months prior to and after starting treatment at Denovo Therapy. PHQ-9 scores prior to establishing care at Denovo Therapy were based on patient estimates, after establishing care scores were recorded in Osmind. Gray shading: represents the area under a simple linear regression of PHQ-9 data from day 1 (first PHQ-9 measurement; measured 3 weeks prior to first ketamine treatment) to day 258 (last PHQ-9 measurement taken during the 8-month treatment regimen). Dotted lines: correspond to ketamine treatment dates (1-14).
fpsyt-13-1020214-g001.jpg
PMC9811588_01_fpsyt-13-1020214-g001.jpg
F1
Questionnaire (PHQ-9), a version of the PRIME-MD diagnostic instrument, was self-administered by the patient using the Osmind electronic health records platform2 at regular intervals (Figure 1 and Table 2). PHQ-9 was used to monitor depression severity, response to treatments, and for diagnostic purposes. Question #9 of the PHQ-9, "Over the past 2 weeks: Thoughts that you would be better off dead, or thoughts of hurting yourself in some way?" and the follow up to Question #9, "Do you have an active intent or plan to harm yourself?" were used to monitor suicidality (Table 2).
Mood scores 7 days before ketamine treatments (left side of graph) were compared to mood scores 7 days after (right side of graph) for ketamine treatment sessions 4-10. Black lines: linear regression lines (days before/after treatment predicting mood) averaged across all sessions. Colored lines: linear regression lines for each individual treatment session. All treatments were administered over the course of 1 h. Treatments 1-3 were excluded from mood score analysis because the time between sessions was less than 7 days; treatments 11-14 were excluded because the patient did not document his mood scores regularly during that time period.
fpsyt-13-1020214-g002.jpg
PMC9811588_01_fpsyt-13-1020214-g002.jpg
F2
Questionnaire (PHQ-9), a version of the PRIME-MD diagnostic instrument, was self-administered by the patient using the Osmind electronic health records platform2 at regular intervals (Figure 1 and Table 2). PHQ-9 was used to monitor depression severity, response to treatments, and for diagnostic purposes. Question #9 of the PHQ-9, "Over the past 2 weeks: Thoughts that you would be better off dead, or thoughts of hurting yourself in some way?" and the follow up to Question #9, "Do you have an active intent or plan to harm yourself?" were used to monitor suicidality (Table 2). Subjective mood scores (scale from 1 to 10, where 1 is worst, and 10 is best) with optional journal entries were recorded by the patient daily in Osmind (Figure 2).